
CorFlow Therapeutics Receives FDA Approval for MOCA-II Pivotal Trial of Innovative Heart Attack Treatment Technology
CorFlow Therapeutics AG a pioneering company in the field of cardiac care targeting microvascular disease, today announced that the U.S. Food & Drug Administration (FDA) has approved the company’s technology for…











